A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Abstract Background Single-agent MEK1/2 inhibition has been disappointing in clinical trials targeting RAS mutant (MT) cancers, probably due to upstream receptor activation, resulting in resistance. We previously found that dual c-MET/MEK1/2 inhibition attenuated RASMT colorectal cancer (CRC) xenogr...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:BJC Reports
Online Access:https://doi.org/10.1038/s44276-025-00133-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44276-025-00133-6

Similar Items